NEW YORK, Jan. 9, 2015 /PRNewswire/ -- Trillium Therapeutics Inc. (NASDAQ: TRIL) based in Toronto, Canada has seen a price surge since its recent listing on the US NASDAQ exchange. The immune-oncology company is focusing efforts on the flagship SIRPaFc compound and is expected to submit an IND in mid-2015. Moving to the US market and consolidating the shares proved to be very profitable for the company and helped appreciate the share price nearly 100% on both the TSX and NSADAQ tickers.
Trillium Therapeutics Inc. is an immune-oncology company dedicated to developing innovative cancer therapies. The lead compound SIRPaFc is a fusion protein that binds to CD47 and prevents cancer cells from delivering a "do not eat" signal; in other words allowing the "destruction" of cancer cells. The company has a bright future in the immune-therapy field; a field that is expected to grow to $35B by the year 2023.
For a more detailed research report with analyst comments and recommendation on Trillium Therapeutics Inc. please follow the link. There is no cost obligation required to view analyst brief:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.